Skip to content
DataLookout
Menu

AncestryNCT07592013

Effect of Ancestry Supplementation in Subjects With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

StatusEnrolling by Invitation
PhaseNot applicable
Primary completion (estimated)

At risk: Primary completion moved at least 31 days later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 18 words Show 4 more changesShow less
    • Primary endpoints: details revised at 1 of 3 entries
    • Primary completion pushed from Oct 2026 to Dec 2026
    • Secondary endpoints: details revised at 15 of 15 entries
    • Publications: details revised at 2 of 2 entries
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

A ≥1 grade hepatic steatosis improvement with no liver fibrosis worsening
Timeframe: From enrollment to the end of treatment at 12 weeks
Increase in Alpha Diversity and/or Enrichment of Beneficial Bacterial Genera in the Gut Microbiota
Timeframe: From baseline to the end of treatment at 12 weeks
Achieving a clinically significant reduction in total body weight by at least 3%
Timeframe: From baseline to the end of treatment at 12 weeks

Secondary (15)

A ≥1 stage liver fibrosis improvement with no hepatic steatosis worsening
Reduction in the degree of obesity according to Body Mass Index (BMI)
Reduction in the degree of obesity according to Body Fat Percentage
Reduction in the degree of obesity according to Visceral Fat Level
Reduction in the degree of obesity according to Waist Circumference
Show 10 moreShow less
Improvement in total cholesterol levels
Improvement in total triglyceride levels
Improvement in High-Density Lipoprotein Cholesterol (HDL-C)
Improvement in Low-Density Lipoprotein Cholesterol (LDL-C)
Improvement in Very Low-Density Lipoprotein Cholesterol (VLDL-C)
Improvement in Alanine Aminotransferase (ALT)
Improvement in Aspartate Aminotransferase (AST)
Improvement in Gamma-glutamyl transferase (GGT)
Improvement in Fasting Glucose
Improvement in Fasting Insulin

Arms and interventions

Ancestry GroupExperimental

Participants in this arm will receive a daily supplement containing a mixture of Mexican-origin foods (nopal, cacao, and cricket) for 3 months. The supplement is named Ancestry. Additionally, participants will receive personalized nutritional guidance from a trained dietitian and will attend monthly follow-up consultations to monitor dietary adherence and overall progress.

Placebo GroupPlacebo comparator

Participants in this arm will receive a daily placebo supplement that is identical in appearance to the experimental supplement but without the active ingredients. Additionally, participants will receive personalized nutritional guidance from a trained dietitian and will attend monthly follow-up consultations to monitor dietary adherence and overall progress.

Dietary supplements: Ancestry

Other: Placebo

Sites

1 site in 1 country

  • Institute of Molecular Biology in Medicine and Gene TherapyGuadalajara, Guadalajara, Mexico